Price movement over the last 24 hours
Agilent Technologies Inc vs Vanguard Short Term Corporate Bond ETF — how do they compare? Agilent Technologies Inc trades at $128.2 (market cap $37.04B), while Vanguard Short Term Corporate Bond ETF trades at $78.57. The key difference: Agilent Technologies Inc pays a 0.78% dividend while Vanguard Short Term Corporate Bond ETF pays none, and Agilent Technologies Inc is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| A | VCSH | |
|---|---|---|
Market Cap | $37.04B | — |
Sector | Health | Fixed Income |
52-Week High | $157.20 | $80.20 |
52-Week Low | $110.24 | $78.61 |
Enterprise Value | $38.59B | — |
Dividend Yield | 0.78% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
VCSH, the Vanguard Short-Term Corporate Bond ETF, trades at $78.85 with minimal daily movement (+0.08%). The technical picture is bearish with moving averages signaling selling pressure, while oscillators remain neutral. Recent news highlights VCSH's competitive advantages including a 4.3% yield and ultra-low 0.03% expense ratio compared to similar bond ETFs. The fund has attracted mixed institutional activity with some firms increasing positions while others reduced exposure.
VCSH offers investors exposure to short-term investment-grade corporate bonds with higher yields than Treasury alternatives, though with slightly more risk. The fund's low costs and monthly distributions make it attractive for income-focused portfolios, but investors face interest rate sensitivity and credit risk from its corporate bond holdings. Current technical weakness suggests potential for near-term price pressure despite the fund's solid fundamental positioning.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →